GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%. The results were presented Sunday during the annual meeting of the America Society of Clinical Oncology.

The post GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO appeared first on MedCity News.

GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.

The post GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact appeared first on MedCity News.

Though GSK divested much of its oncology assets to Novartis in 2015, the company has built back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.

The post At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy appeared first on MedCity News.

GSK gains rights to a Hansoh Pharma antibody drug conjugate that targets a protein abundant on lung cancer cells and other types of solid tumors. The pharmaceutical giant plans to start its own slate of clinical trials with this ADC in 2024.

The post GSK Expands Again in Cancer, Paying Hansoh $185M for Another ADC appeared first on MedCity News.

GSK took Blenrep off the market last year after the multiple myeloma drug failed its confirmatory study. But GSK now says it has interim data showing Blenrep beat a blockbuster Johnson & Johnson drug in a head-to-head Phase 3 study testing it as an earlier line of therapy.

The post GSK Drug Pulled From Market Beats J&J Multiple Myeloma Med in Phase 3 Test appeared first on MedCity News.

The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.

The post FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 Pharmas on Notice appeared first on MedCity News.

Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.

The post Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug appeared first on MedCity News.

FDA approval of GSK’s Ojjaara in myelofibrosis introduces a new competitor to blockbuster Incyte drug Jakafi. Ojjaara was part of GSK’s $1.9 billion acquisition of Sierra Oncology last year.

The post FDA Approves GSK Myelofibrosis Med That Has Edge Over Others in Drug Class appeared first on MedCity News.

GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with the RSV season approaching.

The post GSK Patent Suit Aims to Halt Pfizer’s RSV Vaccine for Adults, But Not Infants appeared first on MedCity News.

FDA approval of GSK’s respiratory syncytial vaccine Arexvy covers adults age 60 and older—an age group at particular risk of developing severe complications from infection. GSK plans to launch Arexvy in time for the 2023/2024 RSV season.

The post First FDA Approval of an RSV Vaccine Goes to GSK appeared first on MedCity News.

Acquiring Bellus Health gives GSK a drug for recurrent chronic cough that could offer a better side effect profile compared to a Merck drug that addresses the same target. Bayer was also pursuing the target, but stopped work on its drug candidate last year.

The post GSK to Gain Chronic Cough Drug With $2B Buyout of Bellus Health appeared first on MedCity News.

GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.

The post GSK Strikes Another Antimicrobial Deal, Paying $90M for Scynexis’s Brexafemme appeared first on MedCity News.

GSK gave Vir Biotechnology a Valentine’s Day break-up message, but it’s not a complete goodbye. Though the two companies are ending their Covid-19 collaboration, they’ll still work together on other respiratory programs, including a prophylactic influenza antibody drug that is in mid-stage clinical development.

The post GSK’s Covid-19 Valentine to Vir Biotech: ‘You Can Go Your Own Way’ appeared first on MedCity News.

The FDA approved GSK drug Jesduvroq for treating anemia in patients with chronic kidney disease. The once-daily pill is the first oral medicine to pass FDA muster in this indication, giving patients a more convenient alternative to injectable anemia therapies.

The post GSK Gets FDA Nod for Drug Treating Anemia From Chronic Kidney Disease appeared first on MedCity News.

GSK is making greater use of artificial intelligence and computational techniques as part of its drug discovery efforts. Speaking during the HLTH conference in Las Vegas, executive Mike Montello likened his company’s techniques to the efforts to study and analyze images from outer space.

The post GSK Digital & Tech Executive Takes Drug-Hunting Inspiration from Outer Space appeared first on MedCity News.

GSK drug otilimab failed a Phase 3 test in rheumatoid arthritis. Though the antibody drug met the main goal in two other pivotal studies, GSK said the limited efficacy in the third study means the company will not seek regulatory approval.

The post ‘Limited efficacy’ dooms GSK drug once considered a blockbuster prospect appeared first on MedCity News.

Respiratory syncytial virus has no approved vaccines anywhere in the world, but the chase to bring the first one to the market is heating up. GSK reported Phase 3 data that position it for regulatory submissions the pharma giant is planning for later this year. Pfizer is also on track to seek regulatory approvals for its RSV vaccine candidate.

The post GSK’s Phase 3 results make it a top contender in chase for first RSV vaccine appeared first on MedCity News.

GSK is partnering with Mersana Therapeutics on the development of an antibody-drug conjugate that is approaching Phase 1 testing. Unlike other ADCs that deliver a toxic drug payload, the Mersana drug is designed to activate the innate immune system to fight tumor cells.

The post GSK pays $100M to partner on a cancer drug with new twist on immunotherapy appeared first on MedCity News.

A panel discussion from a recent Microsoft summit offered insights on how tech companies are closely collaborating with the pharma industry as they seek to repair and improve manufacturing supply chain issues exposed by the Covid-19 pandemic.

The post The power of digital ecosystems to improve pharma supply chain operations appeared first on MedCity News.

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in lieu of the standard regimen of chemotherapy, radiation, and surgery.

The post GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers appeared first on MedCity News.

When consumer healthcare products joint venture Haleon spins out from GSK as an independent company next month, Pfizer will sell its minority stake in the business. Pfizer said that selling its ownership in Haleon is keeping with its focus on developing innovative new medicines and vaccines.

The post After Haleon splits from GSK, Pfizer plans to cash out to the tune of $16B appeared first on MedCity News.

Pfizer and Merck have each won FDA approvals in the past year for new pneumococcal vaccines, but GSK aims to top both of them with its $2.1 billion acquisition of Affinivax. That biotech’s Phase 3-ready vaccine candidate addresses more bacterial strains than any pneumococcal vaccines currently available.

The post GSK gets pneumococcal vaccine contender with $2.1B Affinivax acquisition appeared first on MedCity News.

INVEST Digital Health kicks off today and runs through September 23. Held in a virtual format due to Covid-19, the healthcare conference brings together innovative investors across the healthcare spectrum, prominent industry players and the most promising digital health startups. Register today!

The post INVEST Digital Health preview: The role of digital twins in life sciences appeared first on MedCity News.

When is a skinny label skinny enough to protect a generic drug from claims of patent infringement? The answer remains up to interpretation after an important, controversial decision from the Federal Circuit.

The post Teva’s generic label not skinny enough to protect from $234M damages to GSK appeared first on MedCity News.

The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.

The post Faced with slowing demand, 23andMe cuts 100 employees appeared first on MedCity News.

Our latest eBook offers examples of how some of the players in healthcare are thinking about AI, seeking to apply it across care coordination, drug development and early detection of disease and how to address some of the challenges the technology poses for adoption and implementation.

The post AI in healthcare has spurred exciting applications and collaboration appeared first on MedCity News.

The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.

The post AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate appeared first on MedCity News.

The report also found that 56 percent of physicians have brought up the potential for a digital therapy as an option for their patients, and 26 percent have discussed the option after a patient brought it up.

The post More than half of patients willing to use digital therapeutic, study says appeared first on MedCity News.

The potential rewards for drugmakers’ investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.

The post GSK-Pfizer deal illustrates risks and rewards of moving up the biopharma value chain appeared first on MedCity News.

The oversubscribed round comes just four months after acquisition of GSK’s gene therapy portfolio.

The post Orchard Therapeutics closes $150 million Series C round appeared first on MedCity News.